Joint committee holds 67th virtual meeting
The registration of the "Vondio" product for the treatment of obesity and weight gain associated with health risk factors has been approved by the Food and Drug Authority. This decision is part of efforts to improve treatment options for obesity and enable patients to better manage their health condition. This approval enhances the effectiveness of the treatment and facilitates patients' access to personalized therapeutic options based on a reliable scientific record, thereby contributing to improved public health outcomes and reduced risks linked to obesity.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)